← 홈

림프종 · CD19

118개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 118개
CGTBiologicstaleAFA InsurancePhase 2

Autologous 3rd generation CD19-targeting CAR T cells (Autologous 3rd generation CD19-targeting CAR T cells)

B Cell Lymphoma; B Cell Leukemia · CD19

#CD19#CGT#Phase2#세포유전치료#CAR-T+4
임상시험 1상태 ACTIVE
CGTBiologicstaleMayo ClinicPhase 1

Autologous Anti-CD19 CAR-expressing T-lymphocytes IC19/1563 (Autologous Anti-CD19 CAR-expressing T-lymphocytes IC19/1563)

Recurrent B-Cell Non-Hodgkin Lymphoma; Recurrent Chronic Lymphocytic Leukemia · CD19

#CD19#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 1상태 RECRUITING
CGTBiologicstaleAstraZenecaPhase 1

Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014 (Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014)

Diffuse Large B-Cell Lymphoma, Not Otherwise Specified; Recurrent Diffuse Large B-Cell Lymphoma · EGFR

#EGFR#CGT#Phase1#세포유전치료#CAR-T+5
효능 ORR 1%임상시험 1상태 DISCONTINUED
CGTBiologicBeijing BiotechPhase 2

Autologous BCMA/CD19 dual-target CAR-T module (Autologous BCMA/CD19 dual-target CAR-T module)

Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia; Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL · CD19

#CD19#CGT#Phase2#세포유전치료#CAR-T+4
임상시험 1상태 RECRUITING
CGTBiologicBeijing BiotechPhase 2

Autologous CD19/CD20 dual-target CAR-T module (Autologous CD19/CD20 dual-target CAR-T module)

Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia; Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL · CD19

#CD19#CGT#Phase2#세포유전치료#CAR-T+4
임상시험 1상태 RECRUITING
CGTBiologicBeijing BiotechPhase 2

Autologous CD19/CD22 dual-target CAR-T module (Autologous CD19/CD22 dual-target CAR-T module)

Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia; Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL · CD19

#CD19#CGT#Phase2#세포유전치료#CAR-T+4
임상시험 1상태 RECRUITING
CGTBiologicstaleNational Cancer Institute (NCI)Phase 2

Autologous HuCD19 (Anti-CD19, Autologous HuCD19, Autologous HuCD19 ( Anti-CD19)CAR T cells)

Leukemia, Lymphocytic, Chronic, B-Cell; B-Lymphocytic Leukemia, Chronic · CD19

#CD19#CGT#Phase2#세포유전치료#CAR-T+5
효능 ORR 67%임상시험 1상태 RECRUITING
CGTBiologicstaleZhejiang UniversityPhase 1

Autologous hematopoietic stem cell transplantation combined with CD19 CAR-T cells (Autologous hematopoietic stem cell transplantation combined with CD19 CAR-T cells)

Lymphoma · CD19

#CD19#CGT#Phase1#세포유전치료#CAR-T+3
효능 ORR 88%임상시험 1상태 ACTIVE
CGTBiologicstaleShanghai Exuma Biotechnology Lt…Phase 1

C402-CD19-CAR (C402-CD19-CAR)

Diffuse Large B-cell-lymphoma; DLBCL, Nos Genetic Subtypes · CD19

#CD19#CGT#Phase1#세포유전치료#CAR-T+5
임상시험 1상태 RECRUITING
CGTBiologicstaleCARsgen Therapeutics Co., Ltd.Phase 2

CAR-CD19 T Cells (CAR-CD19 T Cells)

Refractory B-Cell Non-Hodgkin Lymphoma; Relapsed B-cell Non-Hodgkin Lymphoma · CD19

#CD19#CGT#Phase2#세포유전치료#CAR-T+4
임상시험 1상태 ACTIVE
CGTBiologicstaleKang YUPreclinical

CAR-CD19 T cell (CAR-CD19 T cell)

B Cell Lymphoma; B Cell Leukemia · CD19

#CD19#CGT#Preclinical#세포유전치료#CAR-T+4
효능 ORR 67%임상시험 1상태 ACTIVE
CGTBiologicstaleGuangdong Zhaotai Cell Bio-tech…Phase 2

CAT19T2 (CD19 CAR T-Cell, CD19 CAR T-Cell(CAT19T2))

B-cell Acute Lymphoblastic Leukemia; B-Cell Lymphoma, Unspecified · CD19

#CD19#CGT#Phase2#세포유전치료#CAR-T+5
임상시험 1상태 DISCONTINUED
CGTBiologicstaleThird Military Medical Universi…Phase 1

CD19 CAR and PD-1 knock out engineered T-cells (CD19 CAR and PD-1 knock out engineered T-cells)

Acute Lymphoblastic Leukemia; Burkitt Lymphoma · PD-1

#PD-1#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 1상태 ACTIVE
CGTBiologicstaleSecond Affiliated Hospital, Sch…Preclinical

CD19 CAR-T Expressing IL7 and CCL19 (CD19 CAR-T Expressing IL7 and CCL19)

Diffuse Large B-cell Lymphoma; Mantle Cell Lymphoma · CD19

#CD19#CGT#Preclinical#세포유전치료#CAR-T+4
임상시험 1상태 ACTIVE
CGTBiologicstaleSecond Affiliated Hospital, Sch…Phase 1

CD19 CAR-T and CD19 CAR-DC (CD19 CAR-T and CD19 CAR-DC)

Relapsed and Refractory B-cell Lymphoma · CD19

#CD19#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 1상태 ACTIVE
CGTBiologicstalePersonGen BioTherapeutics (Suzh…Preclinical

CD19 CAR-T cells infusion (CD19 CAR-T cells infusion)

Non Hodgkin Lymphoma · CD19

#CD19#CGT#Preclinical#세포유전치료#CAR-T+3
임상시험 1상태 ACTIVE
CGTBiologicstaleiCell Gene TherapeuticsPhase 1

CD19 CARvac T cells (CD19 CARvac T cells)

B Cell Lymphoma; B Cell Leukemia · CD19

#CD19#CGT#Phase1#세포유전치료#CAR-T+4
임상시험 1상태 ACTIVE
CGTBiologicstaleNational Taiwan University Hosp…Phase 1

CD19 Chimeric Antigen Receptor (CAR, CD19 Chimeric Antigen Receptor, CD19 Chimeric Antigen Receptor (CAR) T Cells)

Relapsed/Refractory B-Cell Malignancies · CD19

#CD19#CGT#Phase1#세포유전치료#CAR-T+4
효능 ORR 67%임상시험 1상태 ACTIVE
CGTBiologicstaleUniversity of PennsylvaniaPhase 1

RNA CART19 cells (CD19 RNA redirected autologous T-cells, CD19 RNA redirected autologous T-cells (RNA CART19 cells))

Hodgkin Lymphoma · CD19

#CD19#CGT#Phase1#세포유전치료#CAR-T+3
임상시험 1상태 DISCONTINUED
CGTBiologicstaleSouthwest Hospital, ChinaPhase 2

CD19 or CD20 CAR T cells briging HSCT (CD19 or CD20 CAR T cells briging HSCT)

Lymphoma, Large B-Cell, Diffuse; Leukemia, Lymphocytic, Chronic, B-Cell · CD19

#CD19#CGT#Phase2#세포유전치료#CAR-T+5
임상시험 1상태 ACTIVE

3 / 6 페이지

← 이전다음 →